AustralieFrV1, Main, Exploration, bibRecord, 006E95

Randomized Phase 3 Study of Panitumumab With FOLFIRI vs. FOLFIRI Alone as Second-Line Treatment in Patients With Metastatic Colorectal Cancer

Identifieur interne : 006E95 ( Main/Exploration ); précédent : 006E94; suivant : 006E96

Randomized Phase 3 Study of Panitumumab With FOLFIRI vs. FOLFIRI Alone as Second-Line Treatment in Patients With Metastatic Colorectal Cancer

Auteurs : M. Ducreux [France] ; T. Price [Australie] ; Y. Hotko [Ukraine] ; A. Cervantes [Espagne] ; T. André [France] ; E. Chan [États-Unis] ; F. Lordick [Allemagne] ; A. Rong [États-Unis] ; J. Gansert [États-Unis] ; M. Peeters [Belgique]

Source :

Gastrointestinal Cancer Research : GCR [ 1934-7820 ] ; 2010.

RBID : PMC:3047039

Abstract

Background:

Panitumumab is a fully human anti-epidermal growth factor receptor monoclonal antibody approved as monotherapy for patients with metastatic colorectal cancer. The 181 study was designed to evaluate the efficacy and safety of panitumumab with FOLFIRI vs. FOLFIRI alone as second-line treatment for metastatic colorectal cancer according to tumor KRAS mutational status.

Methods:

This was a randomized, multicenter, phase 3 study. Patients were randomized 1:1 to receive panitumumab 6.0 mg/kg Q2W+FOLFIRI vs. FOLFIRI alone. Patients had metastatic adenocarcinoma of the colon or rectum; only 1 previous chemotherapy regimen for mCRC; ECOG 0-2 and available tumor tissue for biomarker testing. Randomization was stratified by ECOG 0-1 vs. 2, previous oxaliplatin, and previous bevacizumab exposure. The co-primary end points were progression-free survival and overall survival and were independently tested. Originally designed to compare the treatment effect in the all-randomized population, the study was amended to focus on hypothesis testing in the wild-type KRAS subset. KRAS status was determined by a blinded central laboratory using allele-specific PCR prior to the first efficacy analysis.

Results:

From June 2006 to March 2008, a total of 1,186 patients were randomized, signed informed consent, and received treatment. Overall demographics included 61% men, median (range) age 61 years (28–86), 48% ECOG 0, 45% ECOG 1. 1083/1186 pts (91%) had available tumor sample results for KRAS: 597 (55%) wild-type, 486 (45%) mutant. Preliminarily, across both arms, the most common grade 3 or 4 adverse events were neutropenia (19%), diarrhea (12%), rash (8%), fatigue (6%), and dermatitis acneiform (4%).

Conclusions:

Efficacy and safety data will be presented by KRAS status and treatment arm.

Url:

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047039

PubMed: NONE
PubMed Central: 3047039

Affiliations:

Allemagne, Australie, Belgique, Espagne, France, Ukraine, États-Unis
Bade-Wurtemberg, Californie, District de Karlsruhe, Tennessee, Île-de-France
Heidelberg, Paris

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomized Phase 3 Study of Panitumumab With FOLFIRI vs. FOLFIRI Alone as Second-Line Treatment in Patients With Metastatic Colorectal Cancer</title>
<author><name sortKey="Ducreux, M" sort="Ducreux, M" uniqKey="Ducreux M" first="M." last="Ducreux">M. Ducreux</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Institut Gustave Roussy, Villejuif, France;</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Gustave Roussy, Villejuif</wicri:regionArea>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Villejuif</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Price, T" sort="Price, T" uniqKey="Price T" first="T." last="Price">T. Price</name>
<affiliation wicri:level="1"><nlm:aff id="aff2">Queen Elizabeth Hospital, Woodville, Australia;</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Queen Elizabeth Hospital, Woodville</wicri:regionArea>
<wicri:noRegion>Woodville</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hotko, Y" sort="Hotko, Y" uniqKey="Hotko Y" first="Y." last="Hotko">Y. Hotko</name>
<affiliation wicri:level="1"><nlm:aff id="aff3">Uzhgorod National University, Uzhgorod Regional Oncology Dispensary, Uzhgorod, Ukraine;</nlm:aff>
<country xml:lang="fr">Ukraine</country>
<wicri:regionArea>Uzhgorod National University, Uzhgorod Regional Oncology Dispensary, Uzhgorod</wicri:regionArea>
<wicri:noRegion>Uzhgorod</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cervantes, A" sort="Cervantes, A" uniqKey="Cervantes A" first="A." last="Cervantes">A. Cervantes</name>
<affiliation wicri:level="1"><nlm:aff id="aff4">Hospital Clínico, University of Valencia, Spain;</nlm:aff>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Clínico, University of Valencia</wicri:regionArea>
<wicri:noRegion>University of Valencia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Andre, T" sort="Andre, T" uniqKey="Andre T" first="T." last="André">T. André</name>
<affiliation wicri:level="3"><nlm:aff id="aff5">Hôpital Pitié-Salpêtrière, Paris, France;</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Pitié-Salpêtrière, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chan, E" sort="Chan, E" uniqKey="Chan E" first="E." last="Chan">E. Chan</name>
<affiliation wicri:level="2"><nlm:aff id="aff6">Vanderbilt University Medical Center, Nashville, Tennessee;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Tennessee</region>
</placeName>
<wicri:cityArea>Vanderbilt University Medical Center, Nashville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Lordick, F" sort="Lordick, F" uniqKey="Lordick F" first="F." last="Lordick">F. Lordick</name>
<affiliation wicri:level="3"><nlm:aff id="aff7">Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany;</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Nationales Centrum für Tumorerkrankungen, Heidelberg</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Heidelberg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rong, A" sort="Rong, A" uniqKey="Rong A" first="A." last="Rong">A. Rong</name>
<affiliation wicri:level="2"><nlm:aff id="aff8">Amgen Inc., Thousand Oaks, California;</nlm:aff>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Amgen Inc., Thousand Oaks</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Gansert, J" sort="Gansert, J" uniqKey="Gansert J" first="J." last="Gansert">J. Gansert</name>
<affiliation wicri:level="2"><nlm:aff id="aff8">Amgen Inc., Thousand Oaks, California;</nlm:aff>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Amgen Inc., Thousand Oaks</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Peeters, M" sort="Peeters, M" uniqKey="Peeters M" first="M." last="Peeters">M. Peeters</name>
<affiliation wicri:level="1"><nlm:aff id="aff9">University Hospital Ghent, Ghent, Belgium</nlm:aff>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>University Hospital Ghent, Ghent</wicri:regionArea>
<wicri:noRegion>Ghent</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmc">3047039</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3047039</idno>
<idno type="RBID">PMC:3047039</idno>
<idno type="pmid">NONE</idno>
<date when="2010">2010</date>
<idno type="wicri:Area/Pmc/Corpus">001170</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001170</idno>
<idno type="wicri:Area/Pmc/Curation">001031</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001031</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002490</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002490</idno>
<idno type="wicri:Area/Ncbi/Merge">005322</idno>
<idno type="wicri:Area/Ncbi/Curation">005322</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">005322</idno>
<idno type="wicri:doubleKey">1934-7820:2010:Ducreux M:randomized:phase:study</idno>
<idno type="wicri:Area/Main/Merge">007387</idno>
<idno type="wicri:Area/Main/Curation">006E95</idno>
<idno type="wicri:Area/Main/Exploration">006E95</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Randomized Phase 3 Study of Panitumumab With FOLFIRI vs. FOLFIRI Alone as Second-Line Treatment in Patients With Metastatic Colorectal Cancer</title>
<author><name sortKey="Ducreux, M" sort="Ducreux, M" uniqKey="Ducreux M" first="M." last="Ducreux">M. Ducreux</name>
<affiliation wicri:level="1"><nlm:aff id="aff1">Institut Gustave Roussy, Villejuif, France;</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Institut Gustave Roussy, Villejuif</wicri:regionArea>
<wicri:noRegion>Villejuif</wicri:noRegion>
<wicri:noRegion>Villejuif</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Price, T" sort="Price, T" uniqKey="Price T" first="T." last="Price">T. Price</name>
<affiliation wicri:level="1"><nlm:aff id="aff2">Queen Elizabeth Hospital, Woodville, Australia;</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Queen Elizabeth Hospital, Woodville</wicri:regionArea>
<wicri:noRegion>Woodville</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hotko, Y" sort="Hotko, Y" uniqKey="Hotko Y" first="Y." last="Hotko">Y. Hotko</name>
<affiliation wicri:level="1"><nlm:aff id="aff3">Uzhgorod National University, Uzhgorod Regional Oncology Dispensary, Uzhgorod, Ukraine;</nlm:aff>
<country xml:lang="fr">Ukraine</country>
<wicri:regionArea>Uzhgorod National University, Uzhgorod Regional Oncology Dispensary, Uzhgorod</wicri:regionArea>
<wicri:noRegion>Uzhgorod</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cervantes, A" sort="Cervantes, A" uniqKey="Cervantes A" first="A." last="Cervantes">A. Cervantes</name>
<affiliation wicri:level="1"><nlm:aff id="aff4">Hospital Clínico, University of Valencia, Spain;</nlm:aff>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Hospital Clínico, University of Valencia</wicri:regionArea>
<wicri:noRegion>University of Valencia</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Andre, T" sort="Andre, T" uniqKey="Andre T" first="T." last="André">T. André</name>
<affiliation wicri:level="3"><nlm:aff id="aff5">Hôpital Pitié-Salpêtrière, Paris, France;</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital Pitié-Salpêtrière, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chan, E" sort="Chan, E" uniqKey="Chan E" first="E." last="Chan">E. Chan</name>
<affiliation wicri:level="2"><nlm:aff id="aff6">Vanderbilt University Medical Center, Nashville, Tennessee;</nlm:aff>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Tennessee</region>
</placeName>
<wicri:cityArea>Vanderbilt University Medical Center, Nashville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Lordick, F" sort="Lordick, F" uniqKey="Lordick F" first="F." last="Lordick">F. Lordick</name>
<affiliation wicri:level="3"><nlm:aff id="aff7">Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany;</nlm:aff>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Nationales Centrum für Tumorerkrankungen, Heidelberg</wicri:regionArea>
<placeName><region type="land" nuts="1">Bade-Wurtemberg</region>
<region type="district" nuts="2">District de Karlsruhe</region>
<settlement type="city">Heidelberg</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Rong, A" sort="Rong, A" uniqKey="Rong A" first="A." last="Rong">A. Rong</name>
<affiliation wicri:level="2"><nlm:aff id="aff8">Amgen Inc., Thousand Oaks, California;</nlm:aff>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Amgen Inc., Thousand Oaks</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Gansert, J" sort="Gansert, J" uniqKey="Gansert J" first="J." last="Gansert">J. Gansert</name>
<affiliation wicri:level="2"><nlm:aff id="aff8">Amgen Inc., Thousand Oaks, California;</nlm:aff>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Amgen Inc., Thousand Oaks</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Peeters, M" sort="Peeters, M" uniqKey="Peeters M" first="M." last="Peeters">M. Peeters</name>
<affiliation wicri:level="1"><nlm:aff id="aff9">University Hospital Ghent, Ghent, Belgium</nlm:aff>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>University Hospital Ghent, Ghent</wicri:regionArea>
<wicri:noRegion>Ghent</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Gastrointestinal Cancer Research : GCR</title>
<idno type="ISSN">1934-7820</idno>
<idno type="eISSN">1934-7987</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec><title>Background:</title>
<p>Panitumumab is a fully human anti-epidermal growth factor receptor monoclonal antibody approved as monotherapy for patients with metastatic colorectal cancer. The 181 study was designed to evaluate the efficacy and safety of panitumumab with FOLFIRI vs. FOLFIRI alone as second-line treatment for metastatic colorectal cancer according to tumor <italic>KRAS</italic>
 mutational status.</p>
</sec>
<sec><title>Methods:</title>
<p>This was a randomized, multicenter, phase 3 study. Patients were randomized 1:1 to receive panitumumab 6.0 mg/kg Q2W+FOLFIRI vs. FOLFIRI alone. Patients had metastatic adenocarcinoma of the colon or rectum; only 1 previous chemotherapy regimen for mCRC; ECOG 0-2 and available tumor tissue for biomarker testing. Randomization was stratified by ECOG 0-1 vs. 2, previous oxaliplatin, and previous bevacizumab exposure. The co-primary end points were progression-free survival and overall survival and were independently tested. Originally designed to compare the treatment effect in the all-randomized population, the study was amended to focus on hypothesis testing in the wild-type <italic>KRAS</italic>
 subset. <italic>KRAS</italic>
 status was determined by a blinded central laboratory using allele-specific PCR prior to the first efficacy analysis.</p>
</sec>
<sec><title>Results:</title>
<p>From June 2006 to March 2008, a total of 1,186 patients were randomized, signed informed consent, and received treatment. Overall demographics included 61% men, median (range) age 61 years (28–86), 48% ECOG 0, 45% ECOG 1. 1083/1186 pts (91%) had available tumor sample results for <italic>KRAS</italic>
: 597 (55%) wild-type, 486 (45%) mutant. Preliminarily, across both arms, the most common grade 3 or 4 adverse events were neutropenia (19%), diarrhea (12%), rash (8%), fatigue (6%), and dermatitis acneiform (4%).</p>
</sec>
<sec><title>Conclusions:</title>
<p>Efficacy and safety data will be presented by <italic>KRAS</italic>
 status and treatment arm.</p>
</sec>
</div>
</front>
</TEI>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Belgique</li>
<li>Espagne</li>
<li>France</li>
<li>Ukraine</li>
<li>États-Unis</li>
</country>
<region><li>Bade-Wurtemberg</li>
<li>Californie</li>
<li>District de Karlsruhe</li>
<li>Tennessee</li>
<li>Île-de-France</li>
</region>
<settlement><li>Heidelberg</li>
<li>Paris</li>
</settlement>
</list>
<tree><country name="France"><noRegion><name sortKey="Ducreux, M" sort="Ducreux, M" uniqKey="Ducreux M" first="M." last="Ducreux">M. Ducreux</name>
</noRegion>
<name sortKey="Andre, T" sort="Andre, T" uniqKey="Andre T" first="T." last="André">T. André</name>
</country>
<country name="Australie"><noRegion><name sortKey="Price, T" sort="Price, T" uniqKey="Price T" first="T." last="Price">T. Price</name>
</noRegion>
</country>
<country name="Ukraine"><noRegion><name sortKey="Hotko, Y" sort="Hotko, Y" uniqKey="Hotko Y" first="Y." last="Hotko">Y. Hotko</name>
</noRegion>
</country>
<country name="Espagne"><noRegion><name sortKey="Cervantes, A" sort="Cervantes, A" uniqKey="Cervantes A" first="A." last="Cervantes">A. Cervantes</name>
</noRegion>
</country>
<country name="États-Unis"><region name="Tennessee"><name sortKey="Chan, E" sort="Chan, E" uniqKey="Chan E" first="E." last="Chan">E. Chan</name>
</region>
<name sortKey="Gansert, J" sort="Gansert, J" uniqKey="Gansert J" first="J." last="Gansert">J. Gansert</name>
<name sortKey="Rong, A" sort="Rong, A" uniqKey="Rong A" first="A." last="Rong">A. Rong</name>
</country>
<country name="Allemagne"><region name="Bade-Wurtemberg"><name sortKey="Lordick, F" sort="Lordick, F" uniqKey="Lordick F" first="F." last="Lordick">F. Lordick</name>
</region>
</country>
<country name="Belgique"><noRegion><name sortKey="Peeters, M" sort="Peeters, M" uniqKey="Peeters M" first="M." last="Peeters">M. Peeters</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006E95 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006E95 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     PMC:3047039
   |texte=   Randomized Phase 3 Study of Panitumumab With FOLFIRI vs. FOLFIRI Alone as Second-Line Treatment in Patients With Metastatic Colorectal Cancer
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:NONE" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

Serveur d'exploration sur les relations entre la France et l'Australie

Randomized Phase 3 Study of Panitumumab With FOLFIRI vs. FOLFIRI Alone as Second-Line Treatment in Patients With Metastatic Colorectal Cancer

Randomized Phase 3 Study of Panitumumab With FOLFIRI vs. FOLFIRI Alone as Second-Line Treatment in Patients With Metastatic Colorectal Cancer

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.